Phase 2
Completed N=192
Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty
Hip Arthropathy
Source: ClinicalTrials.gov NCT03977454 ↗
Enrolled (actual)
192
Serious AEs
0.0%
Results posted
Sep 2022
Primary outcomePrimary: Daily Opioid Consumption — 29.3; 30.8; 49.6; 51.8 milligram — p=0.69
Summary
This study will assess if preoperative quadratus lumborum block (QLB)/lateral femoral cutaneous nerve block (LFCNB) with ropivacaine and glucocorticoids provide more effective analgesia than periarticular injection (PAI) with the same mixture in total hip arthroplasty (THA).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Daily Opioid Consumption |
29.3; 30.8; 49.6; 51.8; 62.1; 67.7 | 0.69 |
| SECONDARY Change in Pain Intensity While in Hospital |
4.9; 5.0; 4.2; 4.4; 3.9; 4.0 | 0.92 |
| SECONDARY Length of Stay |
47.2; 46.7 | 0.91 |
| SECONDARY Harris Hip Score |
— | — |
| SECONDARY Brief Pain Inventory: Interference |
6.2; 6.3; 2.8; 2.8 | 0.85 |
Eligibility Criteria
Inclusion Criteria
- Elective unilateral primary THA
- All surgical approaches
- American Society of Anesthesiologist (ASA) status I, II and III.
Exclusion Criteria
- Patient refusal;
- Age less than 18 years
- Those with cognitive dysfunction, psychiatric disorder, or non-English speaking patients that cannot consent or communicate clear understanding of the protocol with research team;
- Coagulopathy;
Data sourced from ClinicalTrials.gov (NCT03977454). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.